A comprehensive view of Bristol-Myers Squibb Co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Published: April 26, 2024 by Bristol-Myers Squibb Co.
Bristol Myers reports Q1 US revenues up 7% year-over-year to US$8.5B primarily due to Eliquis, Reblozyl and Opdualag; International revenues remain flat at US$3.4B primarily due to lower average net selling prices
Published: April 25, 2024 by Business Wire
Bristol Myers reports Q1 loss of US$11.91B on revenue of US$11.87B
Published: April 25, 2024 by Associated Press
BRISTOL MYERS SQUIBB CO - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Published: April 25, 2024 by SEC Edgar Filings
BRISTOL MYERS SQUIBB CO - (8-K) - Disclosing Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Published: April 25, 2024 by SEC Edgar Filings

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count